SIRT7 inactivation reverses metastatic phenotypes in epithelial and mesenchymal tumors

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Malik, Shivani ^a,b,f   Villanova, Lidia ^a,b,c,g   Tanaka, Shinji ^d   Aonuma, Misato ^d   Roy, Nilotpal ^e   Berber, Elisabeth ^a,b   Pollack, Jonathan R ^a   Michishita Kioi, Eriko ^d   Chua, Katrin F ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d DAIICHI SANKYO CO   (Japan)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMATIN; SIRT7 PROTEIN, HUMAN; SIRTUIN;

CHROMATIN; DISEASE COURSE; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; GENETIC EPIGENESIS; GENETICS; HUMAN; METASTASIS; PATHOLOGY; PHENOTYPE; PROGNOSIS; SARCOMA; TUMOR CELL LINE;

CELL LINE, TUMOR; CHROMATIN; DISEASE PROGRESSION; EPIGENESIS, GENETIC; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NEOPLASM METASTASIS; PHENOTYPE; PROGNOSIS; SARCOMA; SIRTUINS;

EID: 84928966985     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09841     Document Type: Article

References (34)

1. Paredes, S., Villanova, L. & Chua, K. F. Molecular Pathways: Emerging Roles of Mammalian Sirtuin SIRT7 in Cancer. Clin Cancer Res: an official journal of the American Association for Cancer Research, doi:10.1158/1078-0432.CCR-13-1547 (2014).
2. Haigis, M. C. & Sinclair, D. A. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 5, 253-295, doi:10.1146/annurev.pathol.4.110807. 092250 (2010).
3. Barber, M. F. et al. SIRT7 links H3K18 deacetylation to maintenance ofoncogenic transformation. Nature 487, 114-118, doi:10.1038/nature11043 (2012).
4. Kim, J. K. et al. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology, doi:10.1002/hep.26101 (2012).
5. Ashraf, N. et al. Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer 95, 1056-1061 (2006).
6. de Nigris, F. et al. Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues. Br J Cancer 86, 917-923. (2002).
7. Yu, H. et al. Overexpression of Sirt7 exhibits oncogenic property and serves as a prognostic factor in colorectal cancer. Clin Cancer Res: an official journal of the American Association for Cancer Research, doi:10.1158/1078-0432.CCR-13-2952 (2014).
8. Gupta, G. P. & Massague, J. Cancer metastasis: building a framework. Cell 127, 679-695, doi:10.1016/j.cell.2006.11.001 (2006).
9. Talmadge, J. E. & Fidler, I. J. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 70, 5649-5669, doi:10.1158/0008-5472.CAN-10-1040 (2010).
10. Tam, W. L. & Weinberg, R. A. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 19, 1438-1449, doi:10.1038/nm.3336 (2013).
11. Jawad, M. U. et al. Matrix metalloproteinase 1: role in sarcoma biology. PloS one 5, e14250, doi:10.1371/journal.pone.0014250 (2010).
12. Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243, doi:10.1038/nature11125 (2012).
13. Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22, doi:10.1016/j.ccr.2010.05.026 (2010).
14. Lapointe, J. et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad of Sci of U S A 101, 811-816, doi:10.1073/pnas.0304146101 (2004).
15. Moreno-Bueno, G. et al. Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res 66, 9543-9556, doi:10.1158/0008-5472.CAN-06-0479 (2006).
16. Grunert, S., Jechlinger, M. & Beug, H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nature Rev Mol Cell Biol 4, 657-665, doi:10.1038/nrm1175 (2003).
17. Vleminckx, K., Vakaet, L., Jr., Mareel, M., Fiers, W. & van Roy, F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66, 107-119 (1991).
18. Perl, A. K., Wilgenbus, P., Dahl, U., Semb, H. & Christofori, G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392, 190-193, doi:10.1038/32433 (1998).
19. Seligson, D. B. et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435, 1262-1266 (2005).
20. Xie, D. et al. Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad of Sci of U S A 107, 2485-2490, doi:10.1073/pnas.0908133107 (2010).
21. Min, J. et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nature Med 16, 286-294, doi:10.1038/nm.2100 (2010).
22. Hanyu, A. et al. Functional in vivo optical imaging of tumor angiogenesis, growth, and metastasis prevented by administration of anti-human VEGF antibody in xenograft model of human fibrosarcoma HT1080 cells. Cancer Sci 100, 2085-2092, doi:10.1111/j.1349-7006.2009.01305.x (2009).
23. Byles, V. et al. SIRT1 induces EMT bycooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene 31, 4619-4629, doi:10.1038/onc.2011.612 (2012).
24. DeCraene, B. & Berx, G. Regulatory networks defining EMTduring cancer initiation and progression. Nature Rev Cancer 13, 97-110, doi:10.1038/nrc3447 (2013).
25. Clark-Knowles, K. V., Dewar-Darch, D., Jardine, K. E. & McBurney, M. W. SIRT1 catalytic activity has little effect on tumor formation and metastases in a mouse model of breast cancer. PLoS One 8, e82106, doi:10.1371/journal.pone.0082106 (2013).
26. Shin, J. et al. SIRT7 Represses Myc Activity to Suppress ER Stress and Prevent Fatty Liver Disease. Cell Rep 5, 654-665, doi:10.1016/j.celrep.2013.10.007 (2013).
27. Khanna, C. et al. Toward a drug development path that targets metastatic progression in osteosarcoma. Clin Cancer Res : an official journal of the American Association for Cancer Research 20, 4200-4209, doi:10.1158/1078-0432.CCR-13-2574 (2014).
28. Simic, P. et al. SIRT1 suppresses the epithelial-to-mesenchymal transition in cancer metastasis and organ fibrosis. Cell Rep 3, 1175-1186, doi:10.1016/j.celrep.2013.03.019 (2013).
29. Vakhrusheva, O. et al. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ Res 102, 703-710 (2008).
30. Michishita, E., Park, J. Y., Burneskis, J. M., Barrett, J. C. & Horikawa, I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 16, 4623-4635 (2005).
31. Murayama, A. et al. Epigenetic control of rDNA loci in response to intracellular energy status. Cell 133, 627-639 (2008).
32. Chen, S. et al. Repression of RNA Polymerase I upon Stress Is Caused by Inhibition of RNA-Dependent Deacetylation of PAF53 by SIRT7. Mol Cell 52, 303-313, doi:10.1016/j.molcel.2013.10.010 (2013).
33. Ford, E. et al. Mammalian Sir2 homolog SIRT7 isan activator of RNA polymerase I transcription. Genes Dev 20, 1075-1080 (2006).
34. Kawahara, T. L. et al. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell 136, 62-74, doi:10.1016/j.cell.2008.10.052 (2009).